PepGen Shares Trading Below Cash as Craig-Hallum Starts Coverage with Buy Rating
PepGen has Buy ratings; DM1 drug data mixed, big 2026 results could drive huge upside from very low stock price.
/ 124 items
#XY Analyst Up/Down↓
JPMorgan Sees 127% Upside in Camp4 Therapeutics as It Upgrades to Overweight on CMP-002 Potential
JPMorgan upgrades Camp4 to Overweight, sees strong upside from CMP-002, with trials planned in 2026 and promising early results.
Analysts Reiterate Buy Ratings on Intellia as lonvo-z Shows Deeper Benefits in HAELO Trial
Intellia’s one-time gene therapy cut HAE attacks ~90%, boosting hopes for a lasting treatment; FDA review underway, launch possible in 2027.
Oppenheimer Sees 440% Upside in Acrivon Therapeutics as Key ACR-368 Data Approaches
Cancer drug ACR-368 shows strong early results in endometrial trials biomarker-driven response.
Twist Bioscience Stock Surges Toward $1 Billion Goal as Canaccord Joins Bullish Chorus
Canaccord is bullish on Twist Bioscience, citing AI-driven DNA tech growth, strong revenue gains, and upside to $90 target.
Raymond James Bullish on Dianthus as Claseprubart Outperforms Expectations in Early CAPTIVATE Results
Raymond James reiterated its Strong Buy rating and $125 price target on Dianthus after the company reported strong early data from the Phase 3 CAPTIVATE study of claseprubart in CIDP.